Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

BRISBANE, Calif., Feb. 21, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the fourth quarter and full year ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

InterMune reported Esbriet® (pirfenidone) net revenue in the fourth quarter of 2012 of $8.2 million, compared with $2.7 million in the fourth quarter of 2011.  Esbriet is InterMune's product marketed in Europe for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease of the lungs.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are very pleased with our solid progress in 2012, including five consecutive quarters of Esbriet sales growth since its first European launch in September of 2011.  At year-end 2012, Esbriet was priced and launched in nine of our 15 targeted European countries including the two largest EU markets, Germany and France. 

"In 2013, we expect continued progress in completing pricing and reimbursement processes and additional Esbriet launches in Europe," Mr. Welch continued.  "We also expect to begin building our Esbriet franchise in North America after launching Esbriet in Canada in January of 2013.  Having completed in January the full enrollment of the ASCEND Phase 3 study of pirfenidone intended to support U.S. marketing approval, we are much closer to our goal of bringing Esbriet to IPF patients in the United States, who currently have no approved treatment options."Fourth Quarter and Recent Highlights

  • On October 1, 2012, Esbriet was approved in Canada for the treatment of mild to moderate IPF in adult patients and became commercially available on January 2, 2013.  IPF affects appr
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
    (Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
    (Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
    (Date:12/19/2014)... 19, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... (Bina), a privately held company based in ... provides a big data platform for centralized management ... Bina,s proprietary on-market Genomic Management Solution, Bina-GMS 1 ... perform fast and scalable analyses to maximize the ...
    Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
    ... are pushing state restrictions on human embryonic stem ... beyond President Bush's 2001 order and put Wisconsin's ... ,Rather than adding a layer of unnecessary regulation, ... -- one federal and the other international -- ...
    ... are many ways to assess a workplace but in my opinion, ... of workers and unleashes their talent. , ,Emotional hot buttons are ... they work for or with. They work in a job or ... deeper and more meaningful than a good salary and generous benefits. ...
    ... Now that pharmaceutical giant Abbott Laboratories Inc. ... Wisconsin state line for what figures to be a major ... for creating synergies with the state's existing biotech companies. , ... 15 miles north of its world headquarters in northern Illinois, ...
    Cached Biology Technology:Federal and global guidelines on stem cell research offer a level playing field 2Federal and global guidelines on stem cell research offer a level playing field 3What makes a "best place to work"? 2What makes a "best place to work"? 3What makes a "best place to work"? 4What makes a "best place to work"? 5Abbott Labs campus in Kenosha could send ripples through local biotech 2Abbott Labs campus in Kenosha could send ripples through local biotech 3
    (Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
    (Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
    (Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
    Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
    ... physical world. That,s a fact cancer researchers are beginning to ... mathematics in their efforts to understand how cancer develops -- ... researchers at the University of Michigan Comprehensive Cancer Center, has ... of the top cancer research journals and a new grant ...
    ... once discussed only in scientific or eco-centric circles, has ... sustainability remains elusive. On Friday, scholars and legal ... address how to meet mankind,s present needs without compromising ... The Environmental & Energy Law & Policy Journal,s fifth ...
    ... chemicals from plant material could produce liquid fuel for just ... the infrastructure is set up in the right way, states ... Bioproducts & Biorefining . Developed by scientists at the ... as bioliq, and is able to produce a range of ...
    Cached Biology News:Physics, math provide clues to unraveling cancer 2Symposium at UH will address how to put 'sustainability' into practice 2Novel technology could produce biofuel for around 0.50 a liter ($2.49 a gallon) 2
    Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
    Lysozyme C (W-20)...
    ... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
    ... is a chromogenic substrate ... plasmids. In the presence ... lac + bacterial ... recombinant colonies appear white. ...
    Biology Products: